The company manufactures and trades pharmaceutical, nutraceutical, and herbal products, including Ayurvedic supplements and generic drugs, primarily for the Indian market.
The company operates in a highly fragmented and competitive generic market with no evidence of brand power or cost advantages, as reflected in extremely thin net margins of 2% and a low ROCE of 9.9% which barely covers the cost of capital.
Capital has been deployed into setting up subsidiaries and small manufacturing expansions, but the returns on these investments are mediocre. The company recently utilized reserves for a 1:1 bonus issue rather than cash dividends, suggesting a desire to maintain liquidity while signaling growth.
The investment collapsed as the company's thin 2% margins were obliterated by rising raw material costs and intense generic competition, proving the business lacked any pricing power. The massive concentration of trade receivables, which already represented over half of total assets, eventually led to significant write-offs when key customers defaulted. Furthermore, the aggressive related-party transactions, which were slated to exceed the company's own turnover, resulted in a massive drain of capital to promoter-linked entities, leaving the core business starved of liquidity and unable to service its obligations.
RichFakir rates Walpar Nutritions Ltd's business quality as mediocre — 43/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Walpar Nutritions Ltd is trading about 36% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Walpar Nutritions Ltd is: Not rated. A mediocre business at a cheap price — it does not make our shortlist right now.
RichFakir's educational estimate of Walpar Nutritions Ltd's fair value is about ₹39 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →